You are here:

NICE does not recommend ocrelizumab for primary progressive MS in England and Wales

Published on

Reaction: Ocrelizumab

Consultant neurologist Dr Martin Duddy on NICE'S decision to reject ocrelizumab for early primary progressive MS in England and Wales.

Print this page